IL218628B - Antibodies specific for claudin 6 (6cldn) - Google Patents

Antibodies specific for claudin 6 (6cldn)

Info

Publication number
IL218628B
IL218628B IL218628A IL21862812A IL218628B IL 218628 B IL218628 B IL 218628B IL 218628 A IL218628 A IL 218628A IL 21862812 A IL21862812 A IL 21862812A IL 218628 B IL218628 B IL 218628B
Authority
IL
Israel
Prior art keywords
cldn6
claudin
antibodies specific
antibodies
specific
Prior art date
Application number
IL218628A
Other languages
English (en)
Hebrew (he)
Other versions
IL218628A0 (en
Original Assignee
Ganymed Pharmaceuticals Gmbh
Univ Mainz Johannes Gutenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09014136A external-priority patent/EP2322555A1/en
Application filed by Ganymed Pharmaceuticals Gmbh, Univ Mainz Johannes Gutenberg filed Critical Ganymed Pharmaceuticals Gmbh
Publication of IL218628A0 publication Critical patent/IL218628A0/en
Publication of IL218628B publication Critical patent/IL218628B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
IL218628A 2009-11-11 2012-03-14 Antibodies specific for claudin 6 (6cldn) IL218628B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26020209P 2009-11-11 2009-11-11
EP09014136A EP2322555A1 (en) 2009-11-11 2009-11-11 Antibodies specific for claudin 6 (CLDN6)
US36161810P 2010-07-06 2010-07-06
EP10006956 2010-07-06
PCT/EP2010/006888 WO2011057788A1 (en) 2009-11-11 2010-11-11 Antibodies specific for claudin 6 (cldn6)

Publications (2)

Publication Number Publication Date
IL218628A0 IL218628A0 (en) 2012-05-31
IL218628B true IL218628B (en) 2018-12-31

Family

ID=43480734

Family Applications (2)

Application Number Title Priority Date Filing Date
IL218628A IL218628B (en) 2009-11-11 2012-03-14 Antibodies specific for claudin 6 (6cldn)
IL246710A IL246710B (en) 2009-11-11 2016-07-11 Antibodies specific for claudin 6 (cldn6)

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL246710A IL246710B (en) 2009-11-11 2016-07-11 Antibodies specific for claudin 6 (cldn6)

Country Status (29)

Country Link
US (5) US9487584B2 (OSRAM)
EP (4) EP3305813B1 (OSRAM)
JP (3) JP5889196B2 (OSRAM)
KR (4) KR20210130250A (OSRAM)
CN (4) CN111875703B (OSRAM)
AU (3) AU2010318316B2 (OSRAM)
BR (1) BR112012011143B1 (OSRAM)
CA (2) CA3050655A1 (OSRAM)
CY (2) CY1120300T1 (OSRAM)
DK (2) DK3305813T3 (OSRAM)
ES (3) ES2649389T3 (OSRAM)
HR (2) HRP20171749T1 (OSRAM)
HU (2) HUE049404T2 (OSRAM)
IL (2) IL218628B (OSRAM)
LT (2) LT3305813T (OSRAM)
ME (1) ME02943B (OSRAM)
MX (3) MX347150B (OSRAM)
NO (1) NO2499161T3 (OSRAM)
NZ (2) NZ734307A (OSRAM)
PL (3) PL2499161T3 (OSRAM)
PT (2) PT2499161T (OSRAM)
RS (2) RS56502B1 (OSRAM)
RU (1) RU2675997C2 (OSRAM)
SG (2) SG10201500975YA (OSRAM)
SI (2) SI2499161T1 (OSRAM)
SM (1) SMT201700566T1 (OSRAM)
UA (2) UA128302C2 (OSRAM)
WO (1) WO2011057788A1 (OSRAM)
ZA (1) ZA201202418B (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6358588A (ja) * 1986-08-29 1988-03-14 Toshiba Corp バ−コ−ドèȘ­ć–èŁ…çœź
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US12492253B1 (en) * 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
WO2010094499A1 (en) 2009-02-20 2010-08-26 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
CN111875703B (zh) 2009-11-11 2024-06-04 ćź‰æ–Żæł°æ„ćˆ¶èŻè‚Ąä»œæœ‰é™ć…Źćž ćŻ†è›‹ç™œ6(cldn6)ç‰čćŒ‚æ€§çš„æŠ—äœ“
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
TR201815863T4 (tr) 2010-11-30 2018-11-21 Chugai Pharmaceutical Co Ltd Sitotoksisiteyi indĂŒkleyen terapötik madde.
KR102128027B1 (ko) * 2011-05-13 2020-06-30 가니메드 파마슈티ìčŒìŠ€ êČŒì— ëȠ하 큎띌우딘 6을 발현하는 암 ìč˜ëŁŒìš© 항ìČŽ
CA2832174C (en) * 2011-05-13 2024-02-27 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
CN103320381B (zh) * 2012-03-23 2015-04-15 äžŠæ”·ćž‚ć„żç«„ćŒ»é™ą äž€ç§ć€šèƒœćčČç»†èƒžèĄšéąæ ‡ćż—ç‰©ćŠć…¶ç”šé€”
DK3489261T3 (da) 2012-08-24 2020-12-14 Univ California Antistoffer og vacciner til anvendelse ved behandling af ror1-cancere og hĂŠmning af metastase
BR112015010740B1 (pt) * 2012-11-13 2024-01-30 Biontech Ag Agentes para tratamento de doenças cancerosas expressando claudina
EP3766903A3 (en) * 2012-11-13 2021-02-17 BioNTech SE Bispecific anti claudin xcd3 antibodies for treatment of claudin expressing cancer diseases
EP3027208B1 (en) * 2013-07-31 2020-06-24 Biontech AG Diagnosis and therapy of cancer involving cancer stem cells
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
CA2928671A1 (en) 2013-11-06 2015-05-14 Stemcentrx, Inc. Novel anti-claudin antibodies and methods of use
KR102813659B1 (ko) 2013-11-11 2025-05-28 추가읎 ì„žìŽì•Œìż  가부시킀가읎샀 ê°œëł€ëœ 항ìČŽ ê°€ëł€ì˜ì—­ì„ 포핹하는 항원 êČ°í•© 분자
RS58627B2 (sr) 2014-04-01 2022-06-30 Biontech Cell&Gene Therapies Gmbh Klaudin-6-specifični imuno receptori i t-ćelijski epitopi
MA40921A (fr) * 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
JP7109007B2 (ja) 2016-06-27 2022-07-29 ă‚¶ăƒ»ăƒȘăƒŒă‚žă‚šăƒłăƒ„ăƒ»ă‚Șăƒ–ăƒ»ă‚¶ăƒ»ăƒŠăƒ‹ăƒăƒŒă‚·ăƒ†ă‚€ăƒŒăƒ»ă‚Șăƒ–ăƒ»ă‚«ăƒȘフă‚Șăƒ«ăƒ‹ă‚ą がんæČ»ç™‚ăźç”„ăżćˆă‚ă›
US10882906B2 (en) 2016-12-07 2021-01-05 Osaka University Claudin 5 antibody, and medicine containing said antibody
WO2018207638A1 (ja) * 2017-05-08 2018-11-15 ć›œç«‹ć€§ć­Šæł•äșș性é˜Ș性歊 æŠ—ïœƒïœŒïœ„ïœŽïŒïŒ•æŠ—äœ“ă€ćŠăłăăźæŠ—äœ“ă‚’ć«æœ‰ă™ă‚‹ćŒ»è–Ź
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
CA3126646A1 (en) 2017-09-29 2019-04-04 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
WO2019111871A1 (en) 2017-12-05 2019-06-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137
EP3735463A4 (en) * 2018-01-05 2022-03-02 Chugai Seiyaku Kabushiki Kaisha THERAPEUTIC AGENT INDUCING CYTOTOXICITY
US12493039B2 (en) 2018-10-09 2025-12-09 Fukushima Medical University Biomarker for predicting the prognosis for an endometrial cancer patient
JP7570338B2 (ja) 2019-02-15 2024-10-21 ă‚€ăƒłăƒ†ă‚°ăƒ©ăƒ«ăƒ»ăƒąăƒŹă‚­ăƒ„ăƒ©ăƒŒăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ă‚Żăƒ­ăƒŒăƒ‡ă‚ŁăƒłïŒ–æŠ—äœ“ćŠăłăăźäœżç”š
AU2020241896A1 (en) 2019-03-20 2021-09-23 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
TWI856078B (zh) 2019-03-25 2024-09-21 æ—„ć•†çŹŹäž€äž‰ć…±è‚Ąä»œæœ‰é™ć…Źćž æŠ—é«”â€“ćĄć’Żćč¶è‹ŻäșŒæ°źć‘ŻèĄç”Ÿç‰©ç”ćˆç‰©ă€ć…¶èŁœé€ æ–čæł•ćŠć…¶ç”šé€”
CR20220049A (es) * 2019-07-10 2022-03-02 Chugai Pharmaceutical Co Ltd Moléculas de unión a claudina-6 y usos de las mismas
CN111087465B (zh) * 2019-12-24 2020-12-08 ćčżć·žćŒ»ç§‘性歊 侀种针ćŻčćŻ†è›‹ç™œ6çš„æŠ—äœ“ć¶è”èŻç‰©ćŠćș”甚
US20230220066A1 (en) 2020-03-31 2023-07-13 Chugai Seiyaku Kabushiki Kaisha Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
JP7734753B2 (ja) * 2021-03-05 2025-09-05 ă‚·ăƒŁăƒłăƒă‚€ă€ă‚±ăƒłăƒ‘ăƒŒă‚œăƒŒă€ăƒă‚€ă‚Șăƒ†ă‚ŻăƒŽăƒ­ă‚žăƒŒă€ă‚«ăƒłăƒ‘ăƒ‹ăƒŒă€ăƒȘミテッド æŠ—ïœƒïœŒïœ„ïœŽïŒ–æŠ—äœ“ăŠă‚ˆăłăăźäœżç”š
KR20230156079A (ko) 2021-03-09 2023-11-13 젠윔얎 ìžìœ”íŹë ˆìŽí‹°ë“œ Cd3êłŒ cldn6에 êČ°í•©í•˜ëŠ” ìŽìą…ìŽëŸ‰ìČŽ 항ìČŽ
JPWO2023053282A1 (OSRAM) 2021-09-29 2023-04-06
KR20250046264A (ko) * 2022-07-29 2025-04-02 레전드 ë°”ìŽì˜€í…ŒíŹ 아음랜드 멬믾티드 큎띌우딘6 êČč합 ëȘšìŽì–Ží‹° 및 읎의 용도
EP4566633A1 (en) 2022-10-31 2025-06-11 Astellas Pharma, Inc. Antibody-drug complex containing toll-like receptor 7/8 dual agonist compound
IL319951A (en) 2022-11-30 2025-05-01 Integral Molecular Inc Antibodies targeting claudin 6, including its bispecific formats
CN116064622B (zh) * 2023-02-13 2023-10-13 äŒ˜çżè”›æ€(歊汉)ç”Ÿç‰©ç§‘æŠ€æœ‰é™ć…Źćž Claudin6-mCherryæŠ„ć‘ŠćŸș曠CHO-K1çšłèœŹç»†èƒžæ Șćˆ¶ć€‡ćŠćș”甚
WO2024235175A1 (zh) 2023-05-12 2024-11-21 æ™șæłœç«„ćș·(ćčżć·ž)ç”Ÿç‰©ç§‘æŠ€æœ‰é™ć…Źćž 抗cldn6æŠ—äœ“ćŠć…¶ç”šé€”
US12403202B2 (en) 2023-05-25 2025-09-02 The Regents Of The University Of California Dosage of claudin-6 conjugates for cancer treatment
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119320451B (zh) * 2024-08-21 2025-05-16 ç™Ÿć‰ç”Ÿç‰©ćŒ»èŻ(ćčżć·ž)è‚Ąä»œæœ‰é™ć…Źćž äž€ç§çŽ§ćŻ†èżžæŽ„è›‹ç™œæŠ—äœ“d03ćŠć…¶ćș”甚
CN119371534B (zh) * 2024-08-21 2025-05-27 ç™Ÿć‰ç”Ÿç‰©ćŒ»èŻ(ćčżć·ž)è‚Ąä»œæœ‰é™ć…Źćž äž€ç§çŽ§ćŻ†èżžæŽ„è›‹ç™œæŠ—äœ“e02ćŠć…¶ćș”甚
CN118754987B (zh) * 2024-08-21 2025-02-11 ćčżć·žç™Ÿć‰ç”Ÿç‰©ćˆ¶èŻæœ‰é™ć…Źćž äž€ç§çŽ§ćŻ†èżžæŽ„è›‹ç™œæŠ—äœ“h04ćŠć…¶ćș”甚

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5830755A (en) 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 ĐĄĐŒŃ–Ń‚ĐșлаĐčĐœ Đ‘Ń–Ń‡Đ”ĐŒ БаĐčĐŸĐ»ĐŸĐŽĐ¶Ń–Đșалс ĐĄ.А. ĐšĐŸĐŒĐżĐŸĐ·ĐžŃ†Ń–Ń ĐČĐ°ĐșŃ†ĐžĐœĐž (ĐČĐ°Ń€Ń–Đ°ĐœŃ‚Đž), ŃĐżĐŸŃŃ–Đ± стабілізації qs21 ĐČŃ–ĐŽĐœĐŸŃĐœĐŸ ĐłŃ–ĐŽŃ€ĐŸĐ»Ń–Đ·Ńƒ (ĐČĐ°Ń€Ń–Đ°ĐœŃ‚Đž), ŃĐżĐŸŃŃ–Đ± ĐżŃ€ĐžĐłĐŸŃ‚ŃƒĐČĐ°ĐœĐœŃ ĐșĐŸĐŒĐżĐŸĐ·ĐžŃ†Ń–Ń— ĐČĐ°ĐșŃ†ĐžĐœĐž
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2000073348A2 (en) 1999-06-02 2000-12-07 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO2000035937A1 (en) 1998-12-17 2000-06-22 Human Genome Sciences, Inc. 47 human secreted proteins
US5928631A (en) 1997-06-09 1999-07-27 The Procter & Gamble Company Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US20020127584A1 (en) 1997-09-18 2002-09-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5932445A (en) 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
NZ531664A (en) 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
WO2000026360A1 (en) 1998-11-03 2000-05-11 Adherex Technologies Inc. Compounds and methods for modulating claudin-mediated functions
AU3479700A (en) 1999-02-22 2000-09-14 Incyte Pharmaceuticals, Inc. Genes associated with diseases of the colon
AU2883700A (en) 1999-06-23 2001-01-09 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
HK1047702A1 (zh) * 1999-07-12 2003-03-07 Genentech Inc. 甹侎cd20ç»“ćˆçš„æ‹źæŠ—ć‰‚é˜»æ–­ćŻčć€–æ„æŠ—ćŽŸçš„ć…ç–«ćș”ç­”
CA2402563A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001051513A2 (en) 2000-01-14 2001-07-19 Corixa Corporation Ovarian tumor-associated sequences
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2412211A1 (en) 2000-06-23 2002-01-03 Genetech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP1354040A2 (en) 2000-07-20 2003-10-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7129084B2 (en) 2000-08-03 2006-10-31 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
IL159177A0 (en) * 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
AU2002318371B2 (en) 2001-06-20 2006-06-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2379661A1 (en) * 2002-03-28 2003-09-28 Kursad Turksen Paracellular drug delivery system
KR20040101502A (ko) 2002-04-16 2004-12-02 ì œë„ší…ŒíŹ, ìžíŹ. ìą…ì–‘ì˜ 진닚 및 ìč˜ëŁŒ ë°©ëȕ 및 읎넌 위한 ìĄ°ì„±ëŹŒ
AU2003295328A1 (en) 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
PT1558648E (pt) 2002-10-17 2012-04-23 Genmab As Anticorpos monoclonais humanos contra cd20
JP2006516192A (ja) 2002-10-18 2006-06-29 ă‚žă‚§ăƒăƒłăƒ†ăƒƒă‚Żăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹăƒŒăƒ†ăƒƒăƒ‰ è…«ç˜ăźèšșæ–­ăšæČ»ç™‚ăźăŸă‚ăźç”„æˆç‰©ăšæ–čæł•
AT500651B9 (de) 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
WO2005005601A2 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20080305493A1 (en) 2004-03-08 2008-12-11 Avalon Pharmaceuticals Determining Cancer-Linked Genes and Therapeutic Targets Using Molecular Cytogenetic Methods
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
ITRM20050297A1 (it) * 2005-06-08 2006-12-09 Univ Siena Anticorpi diretti contro la proteina basica della mielina che riconoscono un epitopo del cd64 e uso di essi come immunodepressivi.
RU2515108C2 (ru) 2005-08-19 2014-05-10 ЭббĐČĐž Đ˜ĐœĐș Đ˜ĐŒĐŒŃƒĐœĐŸĐłĐ»ĐŸĐ±ŃƒĐ»ĐžĐœ с ĐŽĐČĐŸĐčĐœŃ‹ĐŒĐž ĐČĐ°Ń€ĐžĐ°Đ±Đ”Đ»ŃŒĐœŃ‹ĐŒĐž ĐŽĐŸĐŒĐ”ĐœĐ°ĐŒĐž Đž Đ”ĐłĐŸ ĐżŃ€ĐžĐŒĐ”ĐœĐ”ĐœĐžŃ
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
RS55740B1 (sr) * 2006-10-02 2017-07-31 Squibb & Sons Inc Humana antitela koja se vezuju za cxcr4 i njihove upotrebe
BRPI0718644A2 (pt) * 2006-11-13 2013-11-26 Arius Res Inc Anticorpo monoclonal isolado, anticorpos humanizado e quimĂ©rico do anticorpo monoclonal isolado, linha de cĂ©lula hibridoma isolada, mĂ©todo para iniciar a citotoxidez induzida por anticorpo de cĂ©lulas cancerosas em uma amostra de tecido selecionada de um tumor humano, cdmab do anticorpo monoclonal isolado ou seu cdmab e usos de um anticorpo monoclonal ou seu cdmab, sozinho ou em conjução com pelo menos um agente quimioterapĂȘutico, e composição
WO2008114733A1 (ja) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗䜓
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2009025759A1 (en) * 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
WO2009028663A1 (ja) 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗䜓
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
JP5848863B2 (ja) * 2008-01-11 2016-01-27 ć›œç«‹ć€§ć­Šæł•äșș 東äșŹć€§ć­Š 抗抗䜓
WO2009126926A2 (en) 2008-04-11 2009-10-15 Bionovo, Inc. Anticancer methods employing extracts of gleditsia sinensis lam
EP2352764B1 (en) 2008-10-14 2018-03-28 Ablynx N.V. AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
DE102009026973A1 (de) 2008-12-18 2010-07-01 Robert Bosch Gmbh Bremsanlage fĂŒr ein Kraftfahrzeug und Verfahren zu ihrer Steuerung
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
WO2010094499A1 (en) 2009-02-20 2010-08-26 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
EP2322555A1 (en) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
CN111875703B (zh) 2009-11-11 2024-06-04 ćź‰æ–Żæł°æ„ćˆ¶èŻè‚Ąä»œæœ‰é™ć…Źćž ćŻ†è›‹ç™œ6(cldn6)ç‰čćŒ‚æ€§çš„æŠ—äœ“
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
CA2832174C (en) * 2011-05-13 2024-02-27 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
EP2605017A1 (de) 2011-12-16 2013-06-19 Protagen AG Markersequenzen fĂŒr gynĂ€kologisches Malignom und deren Verwendung
EP2875046B2 (en) 2012-07-19 2025-04-30 Amgen Inc. Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
BR112015010740B1 (pt) * 2012-11-13 2024-01-30 Biontech Ag Agentes para tratamento de doenças cancerosas expressando claudina
RS58627B2 (sr) * 2014-04-01 2022-06-30 Biontech Cell&Gene Therapies Gmbh Klaudin-6-specifični imuno receptori i t-ćelijski epitopi

Also Published As

Publication number Publication date
CN106432500A (zh) 2017-02-22
NO2499161T3 (OSRAM) 2018-02-03
MX347150B (es) 2017-04-17
ES2988907T3 (es) 2024-11-22
KR102317098B1 (ko) 2021-10-25
EP2499161A1 (en) 2012-09-19
SI2499161T1 (sl) 2017-12-29
EP4461354A2 (en) 2024-11-13
PL3305813T3 (pl) 2021-04-19
CY1123192T1 (el) 2021-10-29
JP2013510808A (ja) 2013-03-28
EP3305813A1 (en) 2018-04-11
CA3050655A1 (en) 2011-05-19
ES2649389T3 (es) 2018-01-11
CN111875703A (zh) 2020-11-03
RU2675997C2 (ru) 2018-12-25
IL246710B (en) 2020-05-31
AU2016202235B2 (en) 2017-12-07
SG10201500975YA (en) 2015-04-29
US20200339677A1 (en) 2020-10-29
UA117799C2 (uk) 2018-10-10
LT2499161T (lt) 2017-11-27
PT3305813T (pt) 2020-04-22
US20240092896A1 (en) 2024-03-21
US11858988B2 (en) 2024-01-02
KR20190031335A (ko) 2019-03-25
IL218628A0 (en) 2012-05-31
JP6125604B2 (ja) 2017-05-10
EP3689911C0 (en) 2024-08-21
SG10202110692WA (en) 2021-12-30
NZ716587A (en) 2017-10-27
EP3305813B1 (en) 2020-01-15
DK3305813T3 (da) 2020-04-20
JP5889196B2 (ja) 2016-03-22
EP3689911A1 (en) 2020-08-05
CA2775373A1 (en) 2011-05-19
ZA201202418B (en) 2013-06-26
LT3305813T (lt) 2020-05-11
EP3689911B1 (en) 2024-08-21
BR112012011143A2 (pt) 2016-11-29
EP4461354A3 (en) 2025-03-19
PL3689911T3 (pl) 2024-11-18
NZ734307A (en) 2020-05-29
CN105348389B (zh) 2019-12-20
MX385874B (es) 2025-03-18
KR20210130250A (ko) 2021-10-29
JP2016047845A (ja) 2016-04-07
CY1120300T1 (el) 2019-07-10
US9932401B2 (en) 2018-04-03
EP2499161B8 (en) 2017-10-25
KR20120115226A (ko) 2012-10-17
SI3305813T1 (sl) 2020-07-31
US20180162938A1 (en) 2018-06-14
HRP20200591T1 (hr) 2020-07-10
ES2784483T3 (es) 2020-09-28
PT2499161T (pt) 2017-12-05
JP6502992B2 (ja) 2019-04-17
EP2499161B1 (en) 2017-09-06
DK2499161T3 (da) 2017-11-27
CN111875703B (zh) 2024-06-04
US9487584B2 (en) 2016-11-08
KR102126964B1 (ko) 2020-06-25
HUE049404T2 (hu) 2020-09-28
KR101960509B1 (ko) 2019-03-20
AU2010318316A1 (en) 2012-04-26
US20160222125A1 (en) 2016-08-04
HUE035516T2 (en) 2018-05-28
US20120308478A1 (en) 2012-12-06
HRP20171749T1 (hr) 2018-01-26
PL2499161T3 (pl) 2018-03-30
CN102741289B (zh) 2016-08-03
AU2018201640B2 (en) 2020-04-30
MX2012005444A (es) 2012-06-19
RS56502B1 (sr) 2018-02-28
CN105348389A (zh) 2016-02-24
IL246710A0 (en) 2016-08-31
RU2012123995A (ru) 2013-12-20
AU2018201640A1 (en) 2018-04-05
UA128302C2 (uk) 2024-06-05
US10745477B2 (en) 2020-08-18
CN102741289A (zh) 2012-10-17
ME02943B (me) 2018-10-20
MX2020011790A (es) 2020-11-24
HK1253300A1 (en) 2019-06-14
JP2017140041A (ja) 2017-08-17
BR112012011143B1 (pt) 2020-05-19
KR20200075903A (ko) 2020-06-26
RS60168B1 (sr) 2020-05-29
AU2010318316B2 (en) 2016-01-14
CN106432500B (zh) 2020-06-02
WO2011057788A1 (en) 2011-05-19
SMT201700566T1 (it) 2018-01-11
CA2775373C (en) 2019-10-29

Similar Documents

Publication Publication Date Title
IL246710B (en) Antibodies specific for claudin 6 (cldn6)
AU2016202235A1 (en) Antibodies specific for Claudin 6 (CLDN6)
GB0708002D0 (en) Antibodies
SI2200700T1 (sl) Nova protitelesa
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
PL3023438T3 (pl) PrzeciwciaƂa anty-gitr
GB0909906D0 (en) Antibodies
GB0821100D0 (en) Antibodies
IL200437A0 (en) Anti-sclerostin antibodies
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
GB0718737D0 (en) Antibodies
GB0702888D0 (en) Novel Antibodies
ZA201006099B (en) Anti-tyrp1 antibodies
GB0920324D0 (en) Antibodies
ZA201007976B (en) Anti-pirb antibodies
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
GB0818356D0 (en) Antibodies
GB0724185D0 (en) Antibodies
GB0823562D0 (en) Antibodies
GB0806230D0 (en) Antibodies
GB0908945D0 (en) Antibodies

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed